A Phase 3 interventional study of bempedoic acid and placebo in Hypercholesterolemia, Atherosclerotic Cardiovascular Disease and Statin Adverse Reaction, sponsored by Esperion Therapeutics, Inc.. Completed at 67 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 8th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 345 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 6th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 3, and was the 8th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Drug: bempedoic acid
Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Other: placebo
bempedoic acid 180 mg tablet
Also known as: ETC-1002
Matching placebo tablet
Also known as: placebo control
Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
PCFB was calculated as the (\[post-Baseline (BL) value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. PCFB in LDL-C was analyzed using analysis of covariance (ANCOVA), with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.
Time frame: Baseline; Week 12
Percent Change From Baseline in LDL-C at Week 24
PCFB was calculated as the (\[post-BL value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available then that single value was used as BL. PCFB in LDL-C was analyzed using ANCOVA, with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.
Time frame: Baseline; Week 24
Percent Change From Baseline in the Lipid Profile at Week 12
PCFB was calculated as: (\[post-BL value minus the BL value\] divided by the BL value) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. apoB and TC BL were defined as the last non-missing value on/prior to Day 1. PCFB was analyzed using ANCOVA, with treatment and group stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing data at Week 12 who were no longer taking study treatment (ST), missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking ST, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.
Time frame: Baseline; Week 12
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline for hsCRP is defined as the last non-missing value on or prior to Day 1. Percent change from Baseline in hsCRP, non-parametric (Wilcoxon rank-sum test) analysis with Hodges-Lehmann estimates and confidence interval was performed.
Time frame: Baseline; Week 12
Absolute Change From Baseline in LDL-C at Week 12 and Week 24
Change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the last two non-missing values on or prior to Day 1.
Time frame: Baseline; Week 12; Week 24
602 participants were screened; out of 602, 345 participants were randomized. 76 participants discontinued investigational medicinal product (IMP), and 18 participants withdrew from the study.
| Milestone | Bempedoic Acid | Placebo |
|---|---|---|
| Started | 234 | 111 |
| Completed | 220 | 107 |
| Not completed | 14 | 4 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Sponsor decision | 5 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Withdrawn by mistake | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
PCFB was calculated as the (\[post-Baseline (BL) value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. PCFB in LDL-C was analyzed using analysis of covariance (ANCOVA), with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.
| percent change | Bempedoic Acid | Placebo |
|---|---|---|
| Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 | -22.58 ± 1.290 | -1.17 ± 1.421 |
PCFB was calculated as the (\[post-BL value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available then that single value was used as BL. PCFB in LDL-C was analyzed using ANCOVA, with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.
| percent change | Bempedoic Acid | Placebo |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 24 | -21.17 ± 1.411 | -2.26 ± 1.552 |
PCFB was calculated as: (\[post-BL value minus the BL value\] divided by the BL value) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. apoB and TC BL were defined as the last non-missing value on/prior to Day 1. PCFB was analyzed using ANCOVA, with treatment and group stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing data at Week 12 who were no longer taking study treatment (ST), missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking ST, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.
| percent change | Bempedoic Acid | Placebo |
|---|---|---|
| non-HDL-C | -18.08 ± 1.114 | -0.14 ± 1.169 |
| TC | -15.37 ± 0.879 | -0.61 ± 0.961 |
| apoB | -14.65 ± 1.080 | 0.32 ± 1.177 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline for hsCRP is defined as the last non-missing value on or prior to Day 1. Percent change from Baseline in hsCRP, non-parametric (Wilcoxon rank-sum test) analysis with Hodges-Lehmann estimates and confidence interval was performed.
| percent change | Bempedoic Acid | Placebo |
|---|---|---|
| Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 12 | -25.37 (-52.75 to 10.78) | 2.67 (-31.07 to 38.04) |
Change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the last two non-missing values on or prior to Day 1.
| mg/dL | Bempedoic Acid | Placebo |
|---|---|---|
| Week 12 | -39.3 ± 33.37 | -3.1 ± 23.66 |
| Week 24 | -37.0 ± 35.27 | -5.1 ± 26.50 |
Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bempedoic Acid | 0/234 (0%) | 14/234 (6%) | 88/234 (37.6%) |
| Placebo | 0/111 (0%) | 4/111 (3.6%) | 45/111 (40.5%) |
| Event | Bempedoic Acid | Placebo |
|---|---|---|
| Angina unstableCardiac disorders | 3/234 | 0/111 |
| Coronary artery diseaseCardiac disorders | 3/234 | 0/111 |
| Acute kidney injuryRenal and urinary disorders | 0/234 | 1/111 |
| Aortic aneurysmCardiac disorders | 0/234 | 1/111 |
| Escherichia pyelonephritisRenal and urinary disorders | 0/234 | 1/111 |
| Escherichia sepsisBlood and lymphatic system disorders | 0/234 | 1/111 |
| NephrolithiasisRenal and urinary disorders | 0/234 | 1/111 |
| Traumatic intracranial haemorrhageNervous system disorders | 0/234 | 1/111 |
| Angina pectorisCardiac disorders | 1/234 | 0/111 |
| Cerebrovascular accidentBlood and lymphatic system disorders | 1/234 | 0/111 |
| Event | Bempedoic Acid | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 7/234 | 9/111 |
| MyalgiaMusculoskeletal and connective tissue disorders | 11/234 | 8/111 |
| FatigueGeneral disorders | 8/234 | 7/111 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/234 | 5/111 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/234 | 4/111 |
| BronchitisInfections and infestations | 6/234 | 6/111 |
| NasopharyngitisInfections and infestations | 3/234 | 5/111 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 10/234 | 5/111 |
| HypertensionVascular disorders | 10/234 | 2/111 |
| Back painMusculoskeletal and connective tissue disorders | 7/234 | 4/111 |
| Age, Continuous(Years) | Bempedoic Acid | Placebo | Total |
|---|---|---|---|
| Mean | 65.2 ± 9.66 | 65.1 ± 9.21 | 65.2 ± 9.50 |
| Sex: Female, Male(Participants) | Bempedoic Acid | Placebo | Total |
|---|---|---|---|
| Female | 133 | 61 | 194 |
| Male | 101 | 50 | 151 |
| Race (NIH/OMB)(Participants) | Bempedoic Acid | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 6 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 16 | 10 | 26 |
| White | 211 | 96 | 307 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline LCL-C, Non-HDL-C, TC, HDL-C, and TG Values(milligrams per deciliter (mg/dL)) | Bempedoic Acid | Placebo | Total |
|---|---|---|---|
| LDL-C | 158.48 ± 40.387 | 155.58 ± 38.812 | 157.55 ± 39.854 |
| Non-HDL-C | 193.49 ± 45.101 | 190.69 ± 43.781 | 192.59 ± 44.637 |
| TC | 245.66 ± 47.252 | 241.09 ± 44.289 | 244.19 ± 46.304 |
| HDL-C | 52.17 ± 14.535 | 50.41 ± 14.384 | 51.60 ± 14.489 |
| TG | 178.96 ± 87.522 | 186.62 ± 96.203 | 181.42 ± 90.336 |
| Baseline Apolipoprotein B (apoB)(mg/dL) | Bempedoic Acid | Placebo | Total |
|---|---|---|---|
| Mean | 141.0 ± 31.64 | 141.9 ± 30.44 | 141.3 ± 31.22 |
| Baseline High-Sensitivity C-Reactive Protein (hsCRP) Values(milligrams per liter (mg/L)) | Bempedoic Acid | Placebo | Total |
|---|---|---|---|
| Median | 2.920 (1.340 to 5.290) | 2.780 (1.210 to 5.150) | 2.900 (1.290 to 5.150) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Mar 2018, 16 months.
Results were first posted in Apr 2020, 2 years after primary completion. A results delay was requested in Sep 2018.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid